However, the power of PROTACs lies in the engagement of E3 ligases, and currently, less than two percent of the vast array of E3 ligases in the human genome have been explored in the TPD field. Dr.

These use E3 ubiquitin ligases to promote the degradation of proteins, rather than inhibiting their function like most traditional small molecules. While a focused class of marketed cancer drugs ...

Matthew Fyfe, newly appointed Chief Scientific Officer at Outrun Therapeutics, commented: “Outrun’s drug hunting approach is among the most innovative in the space, offering a unique opportunity to ...